Eicosapentaenoic acid/docosahexaenoic acid - Pivotal Therapeutics

Drug Profile

Eicosapentaenoic acid/docosahexaenoic acid - Pivotal Therapeutics

Alternative Names: EPA/DHA - Pivotal; PVT-100; Vascazen

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pivotal Therapeutics
  • Class Antihyperlipidaemics; Docosahexaenoic acids; Eicosanoids; Omega 3 fatty acids; Unsaturated fatty acids
  • Mechanism of Action Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Atherosclerosis
  • Clinical Phase Unknown Cardiovascular disorders

Most Recent Events

  • 05 Sep 2017 Phase-III development is ongoing in Atherosclerosis in France (NCT02582710)
  • 05 Jun 2015 Phase-II clinical trials in Atherosclerosis (stabilisation of plaque) in France (PO)
  • 01 Jun 2015 Pivotal Therapeutics initiates enrolment in a phase IIa trial for Atherosclerosis in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top